# TNF (Tumor Necrosis Factor Alpha): Trimeric Cytokine Structure, TNFR1/TNFR2 Signaling, and Anti-TNF Biologics


## Key Takeaways

-   Tumor Necrosis Factor Alpha (TNF) is a pleiotropic cytokine that exists as a soluble homotrimer, mediating its effects through binding to TNFR1 and TNFR2 receptors, initiating divergent signaling cascades that can lead to cell survival, proliferation, apoptosis, or necroptosis.
-   TNFR1 signaling is characterized by the formation of sequential signaling complexes (Complex I and Complex II) that dictate outcomes ranging from NF-κB-driven pro-inflammatory gene expression to Caspase-8-mediated apoptosis or RIPK1/RIPK3-mediated necroptosis.
-   TNFR2 signaling, lacking a death domain, primarily promotes cell survival, T cell proliferation, regulatory T cell function, and tissue repair, often through TRAF-mediated pathways.
-   The *TNF* gene is located on chromosome 6p21.33 within the MHC class III region and is subject to complex transcriptional regulation by factors like NF-κB, AP-1, and Egr-1, with promoter polymorphisms (e.g., TNF-308G>A) influencing susceptibility to inflammatory and autoimmune diseases.
-   Anti-TNF biologics, including monoclonal antibodies (infliximab, adalimumab) and soluble receptor fusion proteins (etanercept), are a cornerstone therapy for chronic inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease by neutralizing TNF.
-   Viruses and bacteria have evolved mechanisms to evade or exploit TNF signaling, with TNF playing a critical role in host defense against intracellular pathogens like *Mycobacterium tuberculosis* and in the pathogenesis of diseases like cerebral malaria.

---

## Executive Summary & Key Metadata

Tumor Necrosis Factor (TNF), historically termed TNF-alpha or cachectin, is a pleiotropic pro-inflammatory cytokine that constitutes the prototypical member of the TNF superfamily (TNFSF). The gene product is a type II transmembrane protein that undergoes proteolytic cleavage to yield a soluble homotrimeric ligand. TNF exerts its biological effects by binding to two distinct receptors, TNFR1 (TNFRSF1A) and TNFR2 (TNFRSF1B), which initiate divergent signaling cascades culminating in outcomes ranging from cell survival and proliferation to apoptosis and necroptosis. Given its central role in the pathogenesis of chronic inflammatory diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis, TNF has become one of the most clinically validated drug targets in modern medicine, with a multi-billion-dollar market of biologic therapeutics.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | TNF |
| **UniProt Accession** | P01375 |
| **Representative PDB ID** | 1TNF |
| **Chromosomal Locus** | 6p21.33 (within the MHC class III region) |
| **Primary Molecular Function** | Cytokine activity; tumor necrosis factor receptor binding; identical protein binding |
| **Disease & Pathology Associations** | Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriasis, Sepsis, Cancer-associated cachexia, Autoimmune hepatitis |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Structure

The *TNF* gene is located on the short arm of chromosome 6 at cytogenetic band 6p21.33, embedded within the class III region of the major histocompatibility complex (MHC). This genomic neighborhood is one of the most gene-dense and polymorphic regions of the human genome. The gene spans approximately 3.0 kilobases (kb) of genomic DNA and consists of four exons separated by three introns. The coding sequence is contained within exons 1 through 4, with the majority of the mature protein sequence encoded by exon 4.

The precise genomic coordinates (GRCh38/hg38) are chr6:31,575,565-31,578,336 (minus strand). The gene is flanked by the *LTA* (Lymphotoxin Alpha) gene upstream and the *LST1* (Leukocyte Specific Transcript 1) gene downstream. The proximity of *TNF* and *LTA* is evolutionarily conserved, and they share regulatory elements, including a bidirectional promoter region.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *TNF* promoter is characterized by a complex array of cis-acting regulatory elements that confer cell-type-specific and stimulus-inducible expression. Unlike many housekeeping genes, the *TNF* promoter lacks a canonical TATA box, instead relying on initiator (Inr) elements and downstream promoter elements (DPE) for basal transcription initiation.

Critical transcription factor binding sites within the proximal promoter (approximately -600 bp to +1 bp relative to the transcription start site) include:

- **NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells):** Multiple binding sites (κB3, κB2, κB1) mediate both positive and negative feedback regulation. The κB3 site at position -627 is particularly important for LPS-inducible expression in macrophages.
- **AP-1 (Activator Protein-1):** Binding sites for Jun/Fos heterodimers are essential for T-cell receptor (TCR)-mediated and PMA/ionomycin-induced TNF expression.
- **NFAT (Nuclear Factor of Activated T-cells):** Cooperative binding with AP-1 is required for robust TNF transcription in T lymphocytes.
- **Egr-1 (Early Growth Response 1):** This transcription factor binds to a GC-rich region and is critical for LPS-induced TNF expression in monocytes.
- **Sp1 (Specificity Protein 1):** Constitutive binding maintains basal promoter activity and chromatin accessibility.
- **C/EBPβ (CCAAT/Enhancer-Binding Protein Beta):** Cooperates with NF-κB in myeloid cells.

Epigenetic regulation is equally critical. The *TNF* locus is maintained in a poised chromatin state in resting macrophages, marked by H3K4me1 (monomethylation of histone H3 at lysine 4) at enhancer regions and H3K27ac (acetylation) upon activation. The TNF promoter also contains CpG islands whose methylation status inversely correlates with transcriptional activity.

### 1.3 Enhancer Elements and 3D Chromatin Architecture

Beyond the proximal promoter, several distal enhancer elements have been identified. A highly conserved enhancer located approximately 2 kb upstream of the transcription start site, termed the TNF-LTA enhancer, contains binding sites for PU.1 and IRF (Interferon Regulatory Factor) family members. This enhancer physically loops to the promoter region in activated macrophages, as demonstrated by Chromosome Conformation Capture (3C) and Hi-C experiments.

The MHC class III region is organized into topologically associating domains (TADs). The *TNF* gene resides within a TAD that encompasses the *LTA*, *LST1*, and *NFKBIL1* genes. Disruption of TAD boundaries in this region has been associated with altered TNF expression and susceptibility to autoimmune diseases.

### 1.4 Isoforms and Transcript Variants

The primary transcript of *TNF* undergoes alternative splicing, generating multiple mRNA isoforms. The canonical transcript (NM_000594.4) encodes the 233-amino acid precursor protein. However, several non-canonical splice variants have been documented:

- **Δ1-TNF:** An isoform lacking exon 1, resulting in a truncated N-terminus. This variant is retained in the cytoplasm and may exert intracellular functions.
- **Δ4-TNF:** A variant lacking exon 4, which encodes the receptor-binding domain. This isoform acts as a dominant-negative regulator by forming non-functional heterotrimers with wild-type TNF.
- **tmTNF:** The membrane-bound form (26 kDa) is generated from the full-length transcript and remains anchored to the cell surface via its transmembrane domain.

The existence of these isoforms adds a layer of complexity to TNF biology, as they can modulate the bioavailability and activity of the canonical cytokine.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human TNF precursor is a 233-amino acid type II transmembrane protein (molecular weight ~26 kDa). The domain architecture, from N-terminus to C-terminus, is as follows:

- **Cytoplasmic Domain (aa 1-35):** This short N-terminal region faces the cytosol. It lacks enzymatic activity but contains motifs that mediate intracellular signaling in the context of reverse signaling through membrane-bound TNF. The cytoplasmic domain is not conserved across species, suggesting a regulatory rather than structural role.
- **Transmembrane Domain (aa 36-56):** A hydrophobic α-helical segment that anchors the protein to the plasma membrane. This domain is also present in the uncleaved membrane-bound form (tmTNF).
- **Extracellular Stalk Region (aa 57-76):** A flexible linker connecting the transmembrane domain to the receptor-binding domain. This region contains the cleavage site for the metalloprotease ADAM17 (TACE - TNF-Alpha Converting Enzyme).
- **TNF Homology Domain (THD) (aa 77-233):** The C-terminal extracellular domain that folds into the canonical TNF "jelly-roll" β-sandwich structure. This domain is responsible for trimerization and receptor binding.

### 2.2 Secondary and Tertiary Structure

The TNF Homology Domain (THD) adopts a classic β-jelly-roll topology, also known as the TNF fold. This fold is shared by all members of the TNF superfamily. The structure consists of two antiparallel β-sheets, each composed of multiple β-strands, arranged in a "Greek key" motif.

For TNF, the THD is composed of ten β-strands (designated A through J). The strands are arranged into two β-sheets: an inner sheet (strands A, H, C, F) and an outer sheet (strands B, G, D, E). The loops connecting these strands are of variable length and are critical for receptor binding specificity.

### 2.3 Quaternary Structure: The Homotrimer

The biologically active form of TNF is a non-covalently associated homotrimer. Three TNF monomers associate via extensive hydrophobic and polar contacts along the interface between the β-sheets. The trimer has a distinctive "bell-shaped" or "cone-shaped" morphology, with the N-termini of the monomers clustered at the narrow top and the C-termini at the wide base.

The trimerization interface buries approximately 4,500 Ų of solvent-accessible surface area per monomer. The stability of the trimer is enhanced by a network of hydrogen bonds and salt bridges. The trimeric assembly is essential for receptor clustering and activation, as each TNF trimer can bind up to three receptor molecules.

The representative crystal structure of the soluble TNF trimer was solved at 2.6 Å resolution (PDB: 1TNF). This structure revealed the precise geometry of the receptor-binding sites, which are located in the grooves between adjacent monomers.

### 2.4 Receptor-Binding Sites and Key Residues

The receptor-binding site on TNF is formed by residues from two adjacent monomers within the trimer. The primary binding interface involves the loop regions connecting β-strands. Key residues include:

- **Tyr87, Tyr119, and Tyr151:** These aromatic residues form a hydrophobic patch that interacts with the cysteine-rich domains (CRDs) of TNFR1.
- **Leu120 and Leu157:** These leucine residues contribute to the hydrophobic core of the binding interface.
- **Glu146 and Glu149:** These acidic residues form salt bridges with basic residues on the receptor.

The binding affinity of soluble TNF for TNFR1 is approximately 0.5 nM, while its affinity for TNFR2 is approximately 0.1 nM. The membrane-bound form of TNF (tmTNF) exhibits a higher affinity for TNFR2 than soluble TNF, a distinction that has significant functional implications.

### 2.5 Post-Translational Modifications

- **Proteolytic Cleavage:** The conversion of membrane-bound TNF (26 kDa) to soluble TNF (17 kDa) is mediated by ADAM17 (TACE). This cleavage occurs at the Ala76-Val77 bond within the extracellular stalk region. ADAM17 activity is regulated by a complex process involving its maturation, trafficking, and inhibition by TIMP3 (Tissue Inhibitor of Metalloproteinases 3).
- **Glycosylation:** TNF contains a single N-linked glycosylation site at Asn45. While glycosylation is not required for trimerization or receptor binding, it may influence the stability and half-life of the protein.
- **Phosphorylation:** The cytoplasmic domain of tmTNF can be phosphorylated, potentially modulating its signaling capacity.

> **Interactive 3D Protein Visualizer: Load TNF (PDB: 1TNF)**
> [Interactive 3D Protein Visualizer: Load TNF (PDB: 1TNF)](/tools/protein-structure-viewer?source=direct&pdbId=1TNF)
>
> *Use the visualizer to explore the trimeric assembly, identify the β-jelly-roll fold of each monomer, and inspect the receptor-binding grooves at the monomer-monomer interfaces. The structure can be rendered in cartoon, surface, or sphere representations, and key residues can be highlighted.*

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The TNF/TNFR Signaling Axis

TNF exerts its biological functions by binding to two distinct cell surface receptors: TNFR1 (TNFRSF1A, p55/p60) and TNFR2 (TNFRSF1B, p75/p80). These receptors belong to the TNF receptor superfamily (TNFRSF) and are characterized by extracellular cysteine-rich domains (CRDs). The intracellular domains of TNFR1 and TNFR2 are structurally distinct, leading to divergent signaling outcomes.

- **TNFR1:** Contains a death domain (DD) in its cytoplasmic tail, making it a member of the death receptor family. TNFR1 is constitutively expressed on most cell types and is the primary mediator of TNF's pro-inflammatory and cytotoxic effects.
- **TNFR2:** Lacks a death domain and instead contains a TRAF (TNF Receptor-Associated Factor) binding motif. TNFR2 expression is more restricted, primarily found on immune cells (Tregs, myeloid cells) and endothelial cells. TNFR2 signaling is generally associated with cell survival, proliferation, and tissue regeneration.

### 3.2 TNFR1 Signaling: The Dichotomy of Survival and Death

Ligation of TNFR1 by soluble TNF trimers triggers a complex signaling cascade that can lead to either cell survival or cell death, depending on the cellular context and post-translational modifications.

**Complex I (Pro-Survival):**

Upon ligand binding, TNFR1 trimerizes, and the death domain (DD) of TNFR1 recruits the adaptor protein TRADD (TNFR1-Associated Death Domain protein) via homotypic DD-DD interactions. TRADD then serves as a scaffold for the recruitment of:

1.  **TRAF2 (TNF Receptor-Associated Factor 2):** An E3 ubiquitin ligase.
2.  **RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1):** A kinase that becomes polyubiquitinated.
3.  **cIAP1/2 (Cellular Inhibitor of Apoptosis Protein 1/2):** E3 ubiquitin ligases that add K63-linked polyubiquitin chains to RIPK1.

The polyubiquitinated RIPK1 serves as a platform for the recruitment of the TAK1 (TGF-β-Activated Kinase 1) complex (TAK1/TAB1/TAB2) and the IKK (IκB Kinase) complex (IKKα/IKKβ/NEMO). This assembly is collectively known as **Complex I**.

Within Complex I, TAK1 phosphorylates and activates IKKβ. Activated IKKβ phosphorylates IκBα (Inhibitor of NF-κB), marking it for K48-linked polyubiquitination and subsequent proteasomal degradation. The degradation of IκBα releases NF-κB (p50/p65 heterodimer), which translocates to the nucleus and drives the transcription of a wide array of pro-inflammatory genes, including cytokines (IL-6, IL-8), chemokines, adhesion molecules (ICAM-1, VCAM-1), and anti-apoptotic proteins (c-FLIP, Bcl-2, cIAPs).

**Complex II (Pro-Apoptotic):**

Under conditions where NF-κB activation is impaired or when cellular stress is high, RIPK1 can become deubiquitinated by CYLD (Cylindromatosis) or A20. Deubiquitinated RIPK1 dissociates from the membrane-associated Complex I and forms a cytosolic complex with TRADD, FADD (Fas-Associated Death Domain protein), and Caspase-8. This complex, known as **Complex IIa**, leads to the autocatalytic activation of Caspase-8, which then initiates the executioner caspase cascade (Caspase-3, -6, -7), culminating in apoptosis.

**Complex IIb (Necroptosis):**

If Caspase-8 activity is inhibited (e.g., by viral inhibitors or pharmacological agents), RIPK1 can interact with RIPK3 (Receptor-Interacting Protein Kinase 3) to form a complex called the **necrosome**. Within the necrosome, RIPK3 phosphorylates MLKL (Mixed Lineage Kinase Domain-Like pseudokinase). Phosphorylated MLKL oligomerizes and translocates to the plasma membrane, where it forms pores, leading to necroptosis—a lytic and highly inflammatory form of cell death.

### 3.3 TNFR2 Signaling: Survival and Immune Regulation

TNFR2 signaling is primarily mediated by TRAF proteins. Upon ligand binding, TNFR2 directly recruits TRAF2 and TRAF1, which in turn recruit cIAP1/2. This complex activates the non-canonical NF-κB pathway, involving the processing of p100 to p52, and the canonical NF-κB pathway to a lesser extent.

Key downstream effects of TNFR2 signaling include:

- **T Cell Survival and Proliferation:** TNFR2 provides co-stimulatory signals to T cells, promoting their survival and clonal expansion.
- **Regulatory T Cell (Treg) Function:** TNFR2 is highly expressed on Tregs, and its signaling enhances their suppressive capacity and stability.
- **Tissue Repair and Regeneration:** TNFR2 signaling on oligodendrocytes, neurons, and cardiomyocytes promotes survival and repair.
- **Myeloid Cell Activation:** TNFR2 can modulate the inflammatory phenotype of macrophages and dendritic cells.

### 3.4 Reverse Signaling via Membrane-Bound TNF

Membrane-bound TNF (tmTNF) can act as a receptor itself, transducing signals into the cell on which it is expressed. This "reverse signaling" is triggered by the binding of soluble TNFRs or antibodies to tmTNF. Reverse signaling through tmTNF has been shown to:

- Induce apoptosis in activated macrophages and T cells.
- Modulate cytokine production.
- Enhance the cytotoxic activity of NK cells.

### 3.5 Protein-Protein Interaction Networks

The TNF signaling pathway involves a highly interconnected network of protein-protein interactions. Key nodes in this network include:

- **TRADD:** The master scaffold for TNFR1 signaling.
- **RIPK1:** A critical decision point between survival, apoptosis, and necroptosis.
- **TRAF2:** A central E3 ligase for both TNFR1 and TNFR2 pathways.
- **NF-κB:** The master transcription factor driving the inflammatory response.

STRING and BioGRID databases list hundreds of experimentally verified interactions for TNF and its signaling partners.

```mermaid
sequenceDiagram
    participant L as "Soluble TNF Trimer"
    participant R1 as "TNFR1"
    participant T as "TRADD"
    participant R2 as "RIPK1"
    participant C as "cIAP1/2"
    participant I as "IKK Complex"
    participant N as "NF-κB"
    participant D as "Nucleus"
    L->>R1: Binds to TNFR1
    R1->>T: Recruits TRADD (DD-DD interaction)
    T->>R2: Recruits RIPK1
    R2->>C: K63-linked polyubiquitination
    C->>I: Recruits IKK complex
    I->>N: Phosphorylates IκBα, releases NF-κB
    N->>D: Translocates to nucleus
    D->>D: Transcribes pro-inflammatory genes (IL-6, IL-8, etc.)
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Genetic Polymorphisms in the TNF Locus

The *TNF* gene is highly polymorphic, with numerous single nucleotide polymorphisms (SNPs) identified in both the promoter and coding regions. These polymorphisms have been extensively studied for their association with susceptibility to infectious and autoimmune diseases.

**Promoter Polymorphisms:**

- **TNF-308G>A (rs1800629):** This is the most extensively studied TNF polymorphism. The A allele (TNF2) is located within a binding site for the transcription factor AP-1 and has been associated with increased TNF production *in vitro* and *in vivo*. The TNF2 allele has been linked to increased susceptibility to:
    - Cerebral malaria
    - Septic shock
    - Rheumatoid Arthritis
    - Systemic Lupus Erythematosus (SLE)
    - Crohn's Disease
- **TNF-238G>A (rs361525):** This polymorphism is located near a Y-box binding site. The A allele has been associated with susceptibility to:
    - Leprosy
    - Chronic Hepatitis B
    - Psoriasis
- **TNF-857C>T (rs1799724):** Associated with altered TNF expression and susceptibility to asthma and tuberculosis.
- **TNF-1031T>C (rs1799964):** Associated with increased TNF production and susceptibility to various inflammatory conditions.

### 4.2 Rare Coding Variants and Mutations

While promoter polymorphisms are common, rare coding mutations in the *TNF* gene that directly cause disease are less frequent. However, several pathogenic variants have been documented:

- **Autoimmune Lymphoproliferative Syndrome (ALPS):** Mutations in the *TNFRSF1A* gene (encoding TNFR1) are the primary cause of the TNFR-associated periodic syndrome (TRAPS). However, mutations in *TNF* itself are not a common cause of ALPS.
- **TNF Receptor-Associated Periodic Syndrome (TRAPS):** This is an autoinflammatory disorder caused by dominant mutations in *TNFRSF1A*. These mutations lead to impaired receptor shedding and altered signaling. While not a mutation in *TNF*, it is a critical differential diagnosis for TNF pathway dysfunction.
- **Loss-of-Function Mutations:** Complete deficiency of TNF in humans is extremely rare. A few cases have been reported with mutations leading to a truncated or non-functional protein. These individuals present with increased susceptibility to intracellular pathogens, particularly *Mycobacterium tuberculosis* and *Salmonella* species, highlighting the critical role of TNF in granuloma formation and host defense.

### 4.3 Somatic Mutations in Cancer

Somatic mutations in the *TNF* gene are not commonly found in cancer genomes. However, the TNF signaling pathway is frequently dysregulated in tumors. Tumors often overexpress TNF, which can promote inflammation, angiogenesis, and immune evasion. Conversely, chronic inflammation driven by TNF can contribute to tumor initiation and promotion. The role of TNF in cancer is context-dependent, acting as a tumor promoter in some settings and a tumor suppressor in others.

### 4.4 Clinical Differentials and Diagnostic Implications

The clinical presentation of TNF pathway dysregulation can be broad. Key differentials to consider include:

- **TRAPS:** Characterized by recurrent fevers, abdominal pain, rash, and joint pain. Diagnosis is confirmed by genetic testing for *TNFRSF1A* mutations.
- **Crohn's Disease and Ulcerative Colitis:** Chronic inflammatory bowel diseases where TNF plays a central pathogenic role. Anti-TNF therapy is a mainstay of treatment.
- **Rheumatoid Arthritis:** A systemic autoimmune disease characterized by chronic joint inflammation. TNF is a key driver of synovitis and joint destruction.
- **Sepsis:** TNF is a primary mediator of the systemic inflammatory response syndrome (SIRS). Elevated TNF levels correlate with poor outcomes.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Evasion of TNF Signaling

Given the potent pro-inflammatory and antiviral functions of TNF, many viruses have evolved sophisticated mechanisms to evade or subvert TNF signaling.

- **Viral FLICE-Inhibitory Proteins (v-FLIPs):** Encoded by gamma-herpesviruses (e.g., Kaposi's Sarcoma-Associated Herpesvirus, KSHV), v-FLIPs inhibit Caspase-8 activation, thereby blocking TNF-induced apoptosis and promoting the survival of infected cells.
- **Viral Inhibitors of RIPK1:** Some viruses, such as Herpes Simplex Virus (HSV), encode proteins that target RIPK1 for degradation or inactivation, thereby blocking both NF-κB activation and necroptosis.
- **Modulation of TNFR Expression:** Viruses can downregulate TNFR1 or TNFR2 expression on the surface of infected cells, making them resistant to TNF-mediated killing.
- **Poxvirus-Encoded TNF Decoy Receptors:** Certain poxviruses (e.g., cowpox virus) encode soluble TNF receptor homologs (e.g., CrmB, CrmC, CrmD) that bind to and neutralize TNF, preventing it from engaging cellular receptors.
- **Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV):** These viruses can modulate TNF signaling to establish chronic infection. HCV core protein has been shown to interfere with TNF-induced apoptosis.

### 5.2 Bacterial Interactions

- ***Mycobacterium tuberculosis*:** TNF is essential for the formation and maintenance of granulomas, which contain the infection. HIV co-infection or anti-TNF therapy can lead to reactivation of latent TB, underscoring the critical role of TNF in host defense.
- ***[Listeria monocytogenes](/knowledge/bacteria/livestock-bacteria/listeria-monocytogenes-circling-disease-ruminants-silage)*:** TNF is required for the innate immune response to Listeria. Mice deficient in TNF or TNFR1 are highly susceptible to Listeria infection.
- ***Salmonella* species:** TNF is critical for controlling Salmonella infection. TNF deficiency leads to disseminated infection.

### 5.3 Parasitic Infections

- ***Plasmodium falciparum*:** TNF is a key mediator of the pathogenesis of cerebral malaria. High TNF levels are associated with severe disease and poor outcomes.
- ***Leishmania* species:** TNF contributes to the control of Leishmania infection by activating macrophages to kill intracellular parasites.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Anti-TNF Biologics

TNF is one of the most successful drug targets in the history of pharmaceutical development. Anti-TNF biologics have revolutionized the treatment of chronic inflammatory diseases. These agents work by neutralizing soluble and/or membrane-bound TNF, thereby blocking its interaction with TNFR1 and TNFR2.

**FDA-Approved Anti-TNF Agents:**

| **Drug Name** | **Type** | **Target** | **Approved Indications** |
|---|---|---|---|
| **Infliximab (Remicade)** | Chimeric monoclonal antibody (mouse variable, human constant) | Soluble and membrane-bound TNF | RA, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis |
| **Adalimumab (Humira)** | Fully human monoclonal antibody | Soluble and membrane-bound TNF | RA, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, Juvenile Idiopathic Arthritis |
| **Etanercept (Enbrel)** | Soluble TNFR2-Fc fusion protein | Soluble TNF and Lymphotoxin Alpha | RA, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, Juvenile Idiopathic Arthritis |
| **Certolizumab Pegol (Cimzia)** | PEGylated Fab' fragment of a humanized monoclonal antibody | Soluble and membrane-bound TNF | RA, Crohn's Disease, Ankylosing Spondylitis, Psoriatic Arthritis |
| **Golimumab (Simponi)** | Fully human monoclonal antibody | Soluble and membrane-bound TNF | RA, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis |

**Mechanism of Action:**

- **Infliximab, Adalimumab, Golimumab:** These full-length antibodies bind to both soluble and membrane-bound TNF. By binding to tmTNF, they can induce reverse signaling and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the depletion of TNF-expressing cells.
- **Etanercept:** This fusion protein consists of the extracellular domain of TNFR2 linked to the Fc portion of human IgG1. It binds to soluble TNF and Lymphotoxin Alpha (LTα). Etanercept does not bind to tmTNF as effectively as the monoclonal antibodies and does not induce ADCC or CDC.
- **Certolizumab Pegol:** This is a PEGylated Fab' fragment that lacks the Fc region. It neutralizes soluble and membrane-bound TNF but does not induce ADCC or CDC. PEGylation increases its half-life.

### 6.2 [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles) of Anti-TNF Response

There is significant inter-individual variability in response to anti-TNF therapy. Pharmacogenomic studies have identified several genetic variants that may predict treatment response:

- **Fcγ Receptor (FCGR) Polymorphisms:** Variants in *FCGR2A* and *FCGR3A* can affect ADCC and the efficacy of monoclonal antibodies.
- **TNF Promoter Polymorphisms:** The TNF-308G>A polymorphism has been studied as a predictor of response, but results have been inconsistent.
- **HLA-DRB1 Shared Epitope:** In RA, the presence of the shared epitope is associated with better response to anti-TNF therapy.
- **Genome-Wide Association Studies (GWAS):** GWAS have identified loci near *CD84*, *PLA2G4A*, and *PDE3A-SLCO1C1* that are associated with anti-TNF response in RA.

### 6.3 Small-Molecule Inhibitors and Emerging Therapeutics

While biologics dominate the TNF-targeting landscape, there is ongoing interest in developing small-molecule inhibitors that can be administered orally.

- **TNF mRNA Translation Inhibitors:** Compounds that inhibit the translation of TNF mRNA, such as the MAPK p38 inhibitors, have been explored. However, p38 inhibitors have shown limited efficacy and significant toxicity in clinical trials.
- **TACE (ADAM17) Inhibitors:** Inhibitors of ADAM17 would prevent the cleavage of membrane-bound TNF to soluble TNF. However, ADAM17 has multiple substrates, and broad inhibition leads to significant on-target toxicity.
- **Dominant-Negative TNF (DN-TNF) Biologics:** These are engineered TNF variants that form non-functional heterotrimers with wild-type TNF, thereby inhibiting its activity. XPro1595 is a DN-TNF biologic that selectively inhibits soluble TNF while preserving the beneficial effects of tmTNF signaling.
- **Anti-TNF Nanobodies:** Single-domain antibodies (VHH) with high affinity for TNF are being developed. These offer advantages in terms of tissue penetration and manufacturing.
- **Oral Small-Molecule TNF Inhibitors:** Recent advances have identified small molecules that bind directly to TNF and prevent its interaction with TNFR1. For example, compounds like UCB-6876 and UCB-5307 have been shown to bind to a pocket on the TNF trimer and allosterically inhibit receptor binding.

### 6.4 Gene Therapy and RNA-Based Therapeutics

- **siRNA/shRNA:** RNA interference approaches to knockdown TNF expression are being explored for local delivery in inflammatory diseases.
- **Antisense Oligonucleotides (ASOs):** ASOs targeting TNF mRNA have been tested in preclinical models.
- **CRISPR-Cas9:** Gene editing approaches to disrupt the *TNF* gene in specific cell populations are under investigation, though delivery remains a major challenge.

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
|---|---|---|
| **NCBI Gene** | 7124 | [https://www.ncbi.nlm.nih.gov/gene/7124](https://www.ncbi.nlm.nih.gov/gene/7124) |
| **Ensembl** | ENSG00000232810 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000232810](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000232810) |
| **UniProt** | P01375 | [https://www.uniprot.org/uniprotkb/P01375](https://www.uniprot.org/uniprotkb/P01375) |
| **RCSB PDB** | 1TNF | [https://www.rcsb.org/structure/1TNF](https://www.rcsb.org/structure/1TNF) |
| **OMIM** | 191160 | [https://www.omim.org/entry/191160](https://www.omim.org/entry/191160) |
| **ClinVar** | Gene: TNF | [https://www.ncbi.nlm.nih.gov/clinvar/?term=TNF%5Bgene%5D](https://www.ncbi.nlm.nih.gov/clinvar/?term=TNF%5Bgene%5D) |
| **STRING** | 9606.ENSP00000356272 | [https://string-db.org/network/9606.ENSP00000356272](https://string-db.org/network/9606.ENSP00000356272) |
| **BioGRID** | 112250 | [https://thebiogrid.org/112250](https://thebiogrid.org/112250) |
| **Gene Ontology (GO)** | GO:0005125 (cytokine activity); GO:0005164 (tumor necrosis factor receptor binding); GO:0033209 (tumor necrosis factor-mediated signaling pathway) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) |
| **Reactome** | R-HSA-75893 (TNF signaling) | [https://reactome.org/content/detail/R-HSA-75893](https://reactome.org/content/detail/R-HSA-75893) |
| **KEGG** | hsa:7124 | [https://www.genome.jp/dbget-bin/www_bget?hsa:7124](https://www.genome.jp/dbget-bin/www_bget?hsa:7124) |

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1.  Eck, M. J., & Sprang, S. R. (1989). The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. *The Journal of Biological Chemistry*, 264(29), 17595–17605. [https://doi.org/10.1016/S0021-9258(18)71511-5](https://doi.org/10.1016/S0021-9258(18)71511-5)
2.  Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H. J., Broger, C., Loetscher, H., & Lesslauer, W. (1993). Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. *Cell*, 73(3), 431–445. [https://doi.org/10.1016/0092-8674(93)90132-a](https://doi.org/10.1016/0092-8674(93)90132-a)
3.  Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N., Schooley, K. A., Gerhart, M., Davis, R., Fitzner, J. N., Johnson, R. S., Paxton, R. J., March, C. J., & Cerretti, D. P. (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. *Nature*, 385(6618), 729–733. [https://doi.org/10.1038/385729a0](https://doi.org/10.1038/385729a0)
4.  Hsu, H., Xiong, J., & Goeddel, D. V. (1995). The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. *Cell*, 81(4), 495–504. [https://doi.org/10.1016/0092-8674(95)90070-5](https://doi.org/10.1016/0092-8674(95)90070-5)
5.  Micheau, O., & Tschopp, J. (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. *Cell*, 114(2), 181–190. [https://doi.org/10.1016/s0092-8674(03)00521-x](https://doi.org/10.1016/s0092-8674(03)00521-x)
6.  Wilson, A. G., Symons, J. A., McDowell, T. L., McDevitt, H. O., & Duff, G. W. (1997). Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. *Proceedings of the National Academy of Sciences of the United States of America*, 94(7), 3195–3199. [https://doi.org/10.1073/pnas.94.7.3195](https://doi.org/10.1073/pnas.94.7.3195)
7.  Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough,